[The specific features of the expression of molecular biological markers for proliferation and apoptosis in patients with lung cancer with epidermal growth factor receptor mutation].
Two hundred and two lung adenocarcinomas were examined for epidermal growth factor receptor (EGFR) mutation: exon 19 deletion and L85R mutation in exon 21. The expression of EGFR, Ki-67, bcl-2, p53 in the lung adenocarcinomas was studied in relation to the type of EGFR mutation. Lung adenocarcinomas harboring the EGFR L858R mutation in exon 21 have a less proliferative activity than those with EGFR mutation in exon 19 and in those without EGFR mutation. The p53 protein expression was higher in a group of adenocarcinomas having the EGFR L858R mutation than in that of adenocarcinomas with EGFR mutation in exon 19. There was no bcl-2 expression in adenocarcinomas showing the EGFR mutation.
A O
AO
Ivantsov
E N
EN
Imianitov
V M
VM
Moiseenko
D E
DE
Matsko
D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D049109:Cell Proliferation; D066246:ErbB Receptors / Q000235:genetics*; D005091:Exons / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009154:Mutation
D014408:Biomarkers, Tumor; C512478:EGFR protein, human; D066246:ErbB Receptors